ROIV ROIVANT SCIENCES LTD Other Situations 8-K Filing 2023 - Announcement of Study Results Roivant Sciences Ltd. announced that its subsidiary Priovant's Phase 2 study evaluating oral brepocitinib in lupus patients did not meet its primary endpoint.Get access to all SEC 8-K filings of the ROIVANT SCIENCES LTD